BioWorld

Dec. 20, 2007

Idera Signs $421M Deal For TLR9 Cancer Agonists

The deal-making furor surrounding Toll-like receptors (TLRs) is continuing, with Merck KGaA agreeing to pay up to $421 million for worldwide rights in cancer indications to Idera Pharmaceuticals Inc.'s for TLR9 agonists. (BioWorld Today) Read More

Galapagos Inks $395M Deal With Lilly For Osteo Drugs

Santaris Gets $700M From GSK In Antiviral LNA-Based Drug Pact

London Leukemia Case Linked To Gene Therapy

Alkermes Gets $166M Boost From GSK's Reliant Buyout

Other News To Note

Clinic Roundup

Financings Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for April 22, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...